Skip to main content

Abbvie M14-361, A Phase I Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination with Carboplatin and Etoposide as a Therapy of Treatment-Naive Extensive Stage Disease Small Cell Lung Cancer

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

AbbVie Inc.

Start Date

September 1, 2015

End Date

January 25, 2017
 

Administered By

Duke Cancer Institute

Awarded By

AbbVie Inc.

Start Date

September 1, 2015

End Date

January 25, 2017